Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Mise à jour : Il y a 4 ans
Référence : NCT00642928

Femme et Homme

  • | Pays :
  • France
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg, 10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of Parkinson's disease patients


Critère d'inclusion

  • Excessive Daytime Sleepiness ,Parkinson's disease

Liens